Definition and Disease Spectrum
Microscopic colitis (MC) is a chronic, immune-mediated inflammatory disorder of the colon characterized by persistent, non-bloody, watery diarrhea, with normal-appearing mucosa on endoscopy but distinctive histopathological features confined to the lamina propria. Two subtypes exist:
- Lymphocytic colitis (LC): Collagenous band ≥10 µm thick, chronic inflammatory infiltrate in surface epithelium.
- Collagenous colitis (CC): Subepithelial collagen deposition ≥10 µm thick (often 20–30 µm), with or without elastin staining.
Both subtypes share overlapping clinical features, risk factors, and treatment responses, suggesting a common pathophysiologic pathway—though LC may present at a slightly younger age and CC is more common in elderly women (F:M ≈ 3:1; peak onset 60–80 years).
Etiology and Pathogenesis
The exact etiology remains elusive but MC is strongly associated with dysregulated mucosal immune responses in genetically susceptible individuals. Key insights:
- Autoimmune link: ↑ prevalence of celiac disease (5–10% of MC vs <1% general population), Hashimoto’s thyroiditis, rheumatoid arthritis, and psoriasis.
- Genetic associations: HLA-DQ1, DQ2, DRB1*01:03 alleles suggest antigen-driven T-cell activation.
- Environmental triggers:
- NSAIDs: Strongest modifiable risk (OR 4.5–8.0); induce epithelial barrier disruption and innate immune activation.
- PPIs: Meta-analyses show association (OR ~2.0), though causality remains debated (confounding by indication likely).
- SSRIs: Emerging evidence of dose-dependent risk (SSRI users have 2–3× higher MC incidence).
- Smoking: Current smoking is protective in Crohn’s but increases MC risk (OR ~2.5), possibly via oxidative stress and altered bile acid metabolism.
Bile acid malabsorption (BAM) coexists in up to 40% of MC cases, contributing to secretory diarrhea. Recent data support a unifying model: mucosal inflammation → impaired ileal FXR/TGR5 signaling → dysregulated bile acid reabsorption → colonic secretion and diarrhea.
Clinical Presentation & Symptom Profile
Chronic (≥4 weeks), non-bloody, watery diarrhea is the hallmark. Key diagnostic clues:
| Symptom | Prevalence | Clinical Significance |
|---|---|---|
| Watery diarrhea (daily, nocturnal) | 100% | ≥3 stools/day; ≥1 nocturnal episode in >50% of patients |
| Urgency | 55–70% | Often severe enough to cause social embarrassment or incontinence |
| Fecal incontinence | 26.3–40% | Associated with rectal hypersensitivity and impaired sphincter control |
| Weight loss | ~30% (mild, <5 kg typically) | Absence of significant weight loss favors MC over IBD/colorectal cancer |
| Abdominal pain | 20–40% | Usually crampy, low-grade; severe pain should raise suspicion for alternate diagnosis |
| Hematochezia | Rare (<5%) | If present, consider IBD, diverticulosis, or ischemia |
Red flags that warrant exclusion of alternative diagnoses:
- Gross blood, significant weight loss (>10% body weight), fever, nocturnal symptoms out of proportion to diarrhea, or family history of IBD/colorectal cancer.
Diagnostic Workup: A Stepwise Approach
1. Clinical and Medication History
- Medications: Detailed review of NSAIDs (including topical/oral), PPIs (>3 months exposure confers risk), SSRIs, statins, and magnesium-containing antacids.
- Autoimmune screen: Ask about celiac disease, thyroid dysfunction, type 1 diabetes.
- Tobacco use history: Pack-years, current/past status.
2. Laboratory Testing
- CBC (look for normocytic anemia in long-standing cases), CRP/ESR (typically normal or mildly elevated; CRP >5 mg/L should prompt IBD evaluation)
- Stool studies:
- C. difficile toxin PCR (mandatory before assuming MC)
- Fecal calprotectin (FC): Usually elevated (100–500 µg/g), but levels <50 µg/g make MC unlikely. FC >250 µg/g should raise concern for IBD or infection.
- Celiac serology: TTG-IgA + total IgA (strongly recommended; 8–10% of MC patients have biopsy-proven celiac disease)
- Basic metabolic panel: Rule out electrolyte imbalance from chronic diarrhea.
3. Endoscopy and Histopathology
- Colonoscopy is required despite normal mucosal appearance (diagnostic yield increases with extensive biopsies).
- Biopsy protocol: Minimum of 6–8 biopsies, including:
- Rectosigmoid (2–3)
- Sigmoid (2–3)
- Descending/transverse colon (1–2)
Why? Histologic activity can be patchy—especially in proximal colon, where collagen thickness may exceed distal sites.
- Histologic diagnostic criteria (Geboes score adapted for MC):FeatureLCCCSubepithelial collagen band ≥10 µmAbsentPresent (often >20 µm)Intraepithelial lymphocytes (IELs)/100 enterocytes≥20≥20Lamina proprial neutrophils/eosinophilsMild ↑Mild–moderate ↑
- Exclusion criteria: No crypt abscesses, basal plasmacytosis, or architectural distortion (features favor IBD).
4. Differentiate Key Mimics
| Condition | Diagnostic Clue |
|---|---|
| Irritable bowel syndrome (IBS-D) | Normal histology; often fluctuating symptoms |
| IBD (UC/Crohn’s) | Endoscopic ulcers, crypt abscesses, elevated FC (>500 µg/g), CRP ↑ |
| Bile acid diarrhea (BAM) | Seaweed scan (SeHCAT) or FGF19 levels ↓; responds to bile acid binders |
| Celiac disease | Positive TTG-IgA + duodenal villous atrophy (even if asymptomatic GI) |
Evidence-Based Management
Goal of Therapy
- Induction: Rapid symptom control (≤2 stools/day, no urgency/incontinence within 6–8 weeks)
- Maintenance: Sustained remission, prevent relapses (50% relapse within 1 year off therapy)
First-Line Induction Therapy
| Scenario | Recommendation | Evidence |
|---|---|---|
| Moderate-severe symptoms (≥4 stools/day, incontinence, nocturnal awakenings) | Budesonide 9 mg/day orally for 6–8 weeks | Meta-analysis (OR 12.3 remission vs placebo; NNT=2). Superior to placebo and mesalamine (RR 2.5). Low systemic exposure minimizes osteoporosis/diabetes risk. |
| Mild symptoms or patient preference | Loperamide PRN + bile acid binder (e.g., cholestyramine 4 g BID) | Effective in BAM-associated MC; avoid in constipation-predominant IBS overlap. |
Second-Line Induction Therapies
| Agent | Dosing & Notes | Evidence Level |
|---|---|---|
| Prednisolone (or prednisone) | 20–40 mg/day × 2–4 weeks, taper over 4–6 weeks | Effective but higher systemic toxicity; reserve for budesonide failures or contraindications |
| Bismuth subsalicylate | 524 mg QID × 8 weeks | NNT=3 for remission (RCTs); safer in elderly, but risk of encephalopathy with renal impairment |
| Mesalamine | 2–3 g/day × 8 weeks | AGA conditionally recommends; UEG/EMCG does not recommend (multiple RCTs negative) |
Maintenance Therapy
- Budesonide 3–6 mg/day for ≥6 months:
- Reduces relapse from ~70% to ~25% at 1 year.
- Taper slowly: e.g., 9→6→3 mg over 8 weeks; monitor for rebound diarrhea.
- Alternative maintenance agents (for steroid-dependent or budesonide-intolerant patients):
- Immunomodulators: Azathioprine 2–2.5 mg/kg/day (TPMT testing required); 6-MP equivalent dosing.
- Biologics:
- Adalimumab: 160/80/40 mg SC at weeks 0/2/4, then 40 mg Q2W (RCT show 37% remission vs 9% placebo).
- Vedolizumab: 300 mg IV at weeks 0/2/6, then Q8W; emerging real-world data support use in refractory MC.
- Methotrexate: 15–25 mg/week SC/PO (small RCTs show benefit).
Adjunctive & Supportive Therapies
- Bile acid binders: First-line if BAM confirmed (SeHCAT <15% or FGF19 <20 pg/mL). Cholestyramine 4 g BID is preferred (better tolerated than colestipol).
- Dietary modifications: Low-FODMAP diet may help overlapping IBS features; avoid NSAIDs, caffeine, alcohol.
- Smoking cessation: Despite paradoxical protective effect of smoking in MC, cardiovascular risks outweigh theoretical benefit.
Surgical Considerations
- Surgery is last-resort (≤5% of cases):
- Diverting ileostomy: For intractable symptoms unresponsive to maximal medical therapy; often reversible.
- Total colectomy: Rare (<20 reported cases); consider only after multidisciplinary review.
Follow-Up & Monitoring
- Clinical remission criteria (UEG/EMCG consensus):
- Mean stools/day <3 AND mean watery stools/day <1 over 7 days (validated diary-based scoring).
- No routine follow-up biopsies: Histologic healing lags behind clinical response; not predictive of relapse.
- Annual screening for celiac disease if seronegative at diagnosis: Repeat TTG-IgA if symptoms recur or new GI manifestations emerge.
Key Prognostic Considerations
- Spontaneous remission occurs in ~25% within 1–3 years, but relapse is common after discontinuation.
- Long-term complications are rare (no increased CRC risk), but quality of life remains impaired due to chronic diarrhea/incontinence.
Summary for Clinical Practice
“Think MC in older adults with chronic non-bloody watery diarrhea and normal colonoscopy. Confirm with ≥8 biopsies, exclude mimics (especially celiac disease and BAM), and start budesonide 9 mg/day for induction. For maintenance, use lowest effective budesonide dose or consider immunomodulators in refractory cases. Avoid NSAIDs/PPIs/SSRIs when possible.”
References
- Vind et al., Am J Gastroenterol. 2023;118(2):252–264.
- Roshan et al., UEG White Book on Microscopic Colitis, 2021.
- Ung et al., Clin Gastroenterol Hepatol. 2024;22(1):78–91.e5.
- Kaser et al., Lancet Gastroenterol Hepatol. 2022;7:648–663.
- Leontiadis et al., World J Gastroenterol. 2020;26(41):6031–6049.
Note: All recommendations align with the most recent international guidelines and reflect current real-world evidence from multicenter registries (e.g., ECCO-EPIDEMIC, Microscopic Colitis Registry).
